Total marrow and lymphoid irradiation as conditioning in haploidentical transplant with posttransplant cyclophosphamide

Posttransplant cyclophosphamide (PTCy) platform has shown low rates of graft-versus-host disease (GVHD) and nonrelapse mortality (NRM) after haploidentical hematopoietic cell transplantation (HaploHCT). However, because of the limited disease control, relapse rate remains a major cause of treatment...

Descripción completa

Detalles Bibliográficos
Autores principales: Al Malki, Monzr M., Palmer, Joycelynne, Tsai, Ni-Chun, Mokhtari, Sally, Hui, Susanta, Tsai, Weimin, Aldoss, Ibrahim, Ali, Haris, Aribi, Ahmed, Cao, Thai, Mei, Mathew, Sandhu, Karamjeet S., Siddiqi, Tanya, Forman, Stephen J., Nakamura, Ryotaro, Marcucci, Guido, Stein, Anthony, Wong, Jeffrey Y. C., Rosenthal, Joseph
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2022
Materias:
Clinical Trials and Observations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9327543/
https://www.ncbi.nlm.nih.gov/pubmed/35838754
http://dx.doi.org/10.1182/bloodadvances.2022007264

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9327543/
https://www.ncbi.nlm.nih.gov/pubmed/35838754
http://dx.doi.org/10.1182/bloodadvances.2022007264

Ejemplares similares